Program Committee
-
Vicki Edwards, RPH Vice President, Pharmacovigilance Excellence and International QPPV
Abbvie, United Kingdom -
Willemijn van der Spuij, MSC Executive Director Europe | International - Patient Safety
Bristol Myers Squibb, Switzerland -
Shahinaz Badr, PHARMD Founder & Managing Director
Vigilance Gate FZ,LLC, United Arab Emirates -
Peter De Veene, MD QPPV
MSD Belgium, Belgium -
Gemma Jimenez Sese Senior Director, Deputy EU QPPV
AstraZeneca, Spain -
Maarten Lagendijk, MSC Deputy EU QPPV
MSD, Netherlands -
Elspeth McIntosh, MBA, RN Director
Castle Pharmacovigilance Ltd, United Kingdom -
Mette Stockner, MD Senior Pharmacovigilance Director
Savara ApS, Denmark -
Doris Irene Stenver, MD, MPA Independent Pharmacovigilance Adviser
Unique Advice, Denmark -
Katarzyna Okrojek-Swiderek, MPHARM, RPH Scientific Director, Safety Evaluation Risk Management (SERM)
GlaxoSmithKline, Poland -
Kiernan Trevett, MSC Quality Policy Lead
Genentech, A Member of the Roche Group, United States -
Nicolas Tsiakkas, MD Scientific Director
Greece -
Angela Van Der Salm, PHD, MSC Director PV, Managing partner
DADA Consultancy B.V., Netherlands -
Magnus Ysander, MD EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden
Have an account?